Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for up to $3.8 bi…

Eli Lilly & Co. Has agreed to acquire AtaiBeckley Inc., a clinical-stage biopharmaceutical company specializing in psychedelic-based therapies, for up to $3.8 billion, marking a significant expansion into the rapidly growing field of psychedelic medicine. The deal, valued at $2.8 billion upfront with potential additional payments of up to $1 billion based on clinical and regulatory milestones, underscores the pharmaceutical giant’s strategic push to diversify beyond its core cardiometabolic and obesity drug franchises.

The acquisition, announced on July 16, 2026, sees Lilly paying $6.75 per share in cash for AtaiBeckley, a 26% premium over the company’s closing price of $5.36 on July 15. This offer represents a 40% premium to the 30-day volume-weighted average price of AtaiBeckley’s stock, reflecting the high valuation of its pipeline. The transaction includes contingent value rights (CVRs) that could add up to $2.50 per share, contingent on the success of AtaiBeckley’s lead candidates, BPL-003 and VLS-01.

AtaiBeckley’s lead program, BPL-003, is a synthetic form of 5-MeO-DMT administered as a nasal spray for treatment-resistant depression, a condition affecting millions of patients who do not respond to conventional antidepressants. The drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is in Phase 3 trials, with early results expected in 2029. A separate program, VLS-01, a DMT-based buccal film, is in Phase 2b development for the same indication, while EMP-01, a formulation of (R)-MDMA, targets social anxiety disorder.

The deal aligns with broader industry trends, as major pharmaceutical companies increasingly invest in psychedelic therapies. Eli Lilly’s move follows AbbVie’s $1.2 billion acquisition of a psychedelic depression drug from Gilgamesh Pharmaceuticals in 2025. The Trump administration’s April 2026 executive order, which directed regulators to fast-track reviews of psychedelic treatments and boost federal research funding, has further accelerated interest in the sector.

Lilly’s acquisition of AtaiBeckley is part of a larger strategy to expand its neuroscience portfolio. The company has been actively acquiring biotech firms, including Centessa Pharmaceuticals for $7.8 billion in June 2026 and several vaccine developers earlier in 2026. This latest deal leverages Lilly’s profitability from its obesity and diabetes drugs, which have generated billions in revenue, to fund its foray into mental health innovation.

AtaiBeckley’s shares surged over 30% in premarket trading following the announcement, while other psychedelic-focused companies, such as Enveric Biosciences and GH Research, also saw gains. The transaction, expected to close in the third quarter of 2026, requires shareholder approval and regulatory clearances. AtaiBeckley’s board has endorsed the deal, with key stakeholders, including its largest shareholder, Christian Angermayer, expressing confidence in the partnership.

The acquisition highlights the growing recognition of psychedelic therapies as a potential solution for mental health conditions with limited treatment options. AtaiBeckley’s approach, which focuses on restoring synaptic connectivity through rapid-acting neuroplastogens, contrasts with traditional antidepressants that target neurotransmitter levels. Analysts suggest the deal could position Lilly as a leader in a market projected to reach $12 billion by 2034, rivaling the current $8 billion antidepressant sector.

However, the success of the acquisition hinges on the clinical and regulatory outcomes of AtaiBeckley’s pipeline. BPL-003’s Phase 3 trials will be critical, as will the company’s ability to navigate the complex regulatory landscape for psychedelics. Lilly’s resources and expertise in drug development are expected to accelerate these efforts, though challenges such as public perception, legal hurdles, and long-term efficacy data remain.

As the psychedelic medicine space evolves, Eli Lilly’s investment signals a shift in pharmaceutical priorities, blending innovation with the pursuit of new revenue streams. The deal not only bolsters Lilly’s neuroscience portfolio but also reflects the industry’s broader embrace of unconventional therapies to address unmet medical needs.